,
Rinvoq and Opzelura for Vitiligo: What the JAK Inhibitors Can and Cannot Do
Opzelura (ruxolitinib cream) is approved, Rinvoq (upadacitinib) has a positive EU opinion since June 2026. What the phase 3 trials showed, who qualifies, side effects, prices and how the JAK inhibitors fit with UVB phototherapy.
.jpg)
New comment